Breaking News, Collaborations & Alliances

Altus Reacquires Rights to ALTU-135

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Altus Pharmaceuticals has reacquired development and commercialization rights to ALTU-135 from Dr. Falk Pharma, terminating their development and commercialization collaboration in Europe and countries of the former Soviet Union, Israel and Egypt. Altus’ enzyme combination, ALTU-135, is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals, including cystic fibrosis patients. Under the agreement, Altus regains control of all of the assets re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters